Tickerover
Healthcare

AORT Stock Analysis

Artivion, Inc. · current price $26.77 (+0.26% today)

Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
★★★
Average
📊

The six-pillar scorecard

Momentum
55
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
88
High quality
profitability & balance sheet
Valuation
35
Getting pricey
is the price fair?
Sentiment
48
Mixed views
analyst & crowd mood
Risk
39
Above-avg risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 5555Near 52w highNear 52w high: 100100RSI zoneRSI zone: 7070Trend strengthTrend strength: 6565Analyst consensusAnalyst consensus: 7070News sentimentNews sentiment: 9595Earnings accelerationEarnings acceleration: 8888
Margin profileWhat survives each step down the income statement.
GrossGross: 64.4%64.4%OperatingOperating: 9.0%9.0%NetNet: -0.7%-0.7%Free cash flowFree cash flow: -1.9%-1.9%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +34.5% vs estimate+34%2026-062026-03: -35.1% vs estimate-35%2026-032025-12: -3.4% vs estimate-3%2025-122025-09: +5.3% vs estimate+5%2025-09
👁

Hype Check

Reading AORT’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading AORT’s filings…

📣

Latest earnings

LAST EARNINGS Artivion, Inc. (AORT)

Latest earnings

EPS
$0.16 vs $0.15 est · +5.3% vs estimate BEAT
Revenue
$125.8M · +10.9% YoY
Stock reaction (1M)
-3.2%
Beat streak
2 of last 4 quarters
💰

Valuation

P/E
34.2×
Forward P/E
34.2×
PEG
643.75
Price / Sales
2.8×
Price / Book
2.9×
EV / EBITDA
25.7×
Analyst target
$42.15
Target range
$38.00 – $48.00
Implied upside
+57.4%
🩺

Financial health

Gross margin
64.4%
Operating margin
9.0%
Net margin
-0.7%
FCF margin
-1.9%
Return on equity
-0.7%
Debt / equity
0.92
Revenue growth YoY
+11.3%
📈

Technicals

$19.1652-week range$48.25
RSI (14)
49
50-day MA
$25.56
200-day MA
$34.22
ATR (14)
1.18
Beta
1.25
1-month return
-3.2%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.16$0.15+5.3%Beat
2025-12-31$0.17$0.18-3.4%Miss
2026-03-31$0.08$0.12-35.1%Miss
2026-06-30$0.13$0.10+34.5%Beat
Beat 2 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.07%
Beta
1.25
📰

Latest news on AORT

🔗

Similar stocks in Healthcare

Frequently asked

What is AORT's Quant Score?

Artivion, Inc. (AORT) currently has a TickerMover Quant Score of 59/100, rated ★★★ Average. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Artivion, Inc. (AORT) a buy?

TickerMover does not give buy or sell recommendations. AORT scores 59/100 (★★★ Average) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is AORT's score updated?

AORT's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for AORT →